Afferent Pharmaceuticals Raises $23M
Palo Alto-based Afferent Pharmaceuticals, a developer of chronic pain treatments, has raised $23M in a Series A financing round, the firm said today. The round was led by Third Rock Ventures and Pappas Ventures, and also included Domain Associates and New Leaf Venture Partners. Afferent is licensing Roche's P2X31 receptor program to Afferent as part of the deal. According to Afferent, the funding will go to accelerate development of the P2X3 receptor targeted pain therapies. Afferent is headed by Anthony Ford, Ph.D., former vice president of research at Roche.
posted on Wednesday, December 16, 2009
Related companies:
Afferent Pharmaceuticals, Inc.
Related stories:
> Third Rock Ventures Raises $426M Fund, Sets Up Shop In San Francisco
> Attenua Picks Up $35M to Treat Chronic Cough
> Bridge Pharmaceuticals Raises $35M
> MicuRx Raises $10M
> MAP Pharmaceuticals Raises $50M
silicontap.com Home